Control Empresarial De Capital Acquires 8,264,462 Shares of ProKidney Corp. (NASDAQ:PROK) Stock

ProKidney Corp. (NASDAQ:PROKGet Free Report) insider Control Empresarial De Capital bought 8,264,462 shares of the stock in a transaction that occurred on Tuesday, June 11th. The stock was acquired at an average cost of $2.42 per share, for a total transaction of $19,999,998.04. Following the purchase, the insider now owns 71,560,107 shares of the company’s stock, valued at $173,175,458.94. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

ProKidney Trading Down 3.0 %

Shares of ProKidney stock traded down $0.07 during trading on Tuesday, reaching $2.24. The company’s stock had a trading volume of 279,272 shares, compared to its average volume of 777,224. The stock has a 50-day moving average price of $2.97 and a two-hundred day moving average price of $2.05. The stock has a market capitalization of $513.72 million, a P/E ratio of -4.18 and a beta of 1.20. ProKidney Corp. has a one year low of $1.12 and a one year high of $13.51.

ProKidney (NASDAQ:PROKGet Free Report) last announced its earnings results on Friday, May 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.09. As a group, sell-side analysts anticipate that ProKidney Corp. will post -0.56 EPS for the current fiscal year.

Institutional Investors Weigh In On ProKidney

A number of institutional investors and hedge funds have recently made changes to their positions in PROK. Federated Hermes Inc. lifted its position in ProKidney by 10,984.7% during the 4th quarter. Federated Hermes Inc. now owns 113,286 shares of the company’s stock valued at $202,000 after purchasing an additional 112,264 shares during the period. SG Americas Securities LLC raised its stake in shares of ProKidney by 174.2% during the fourth quarter. SG Americas Securities LLC now owns 46,829 shares of the company’s stock worth $83,000 after buying an additional 29,749 shares during the last quarter. Finally, Zullo Investment Group Inc. bought a new position in ProKidney in the first quarter valued at approximately $32,000. Institutional investors own 51.59% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Bank of America increased their price objective on ProKidney from $3.00 to $4.00 and gave the stock a “neutral” rating in a research note on Wednesday, May 29th. Jefferies Financial Group cut their price target on shares of ProKidney from $15.00 to $6.00 and set a “buy” rating for the company in a report on Monday, June 10th. Finally, Morgan Stanley initiated coverage on shares of ProKidney in a research report on Thursday, March 7th. They issued an “equal weight” rating and a $3.00 price target on the stock.

Get Our Latest Stock Report on PROK

ProKidney Company Profile

(Get Free Report)

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.

See Also

Insider Buying and Selling by Quarter for ProKidney (NASDAQ:PROK)

Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.